Remegen Co., Ltd.
Clinical trials sponsored by Remegen Co., Ltd., explained in plain language.
A Chinese biopharmaceutical company developing antibody-drug conjugates and other targeted therapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug trial aims to ease droopy eyelids and double vision Results expected Dec 2026 (estimated) 🚀 Make-or-break
- New drug combo aims to improve First-Line colorectal cancer treatment Results expected May 2027 (estimated)
-
New drug telitacicept tested for MS Flare-Ups
Disease control Stopped earlyThis phase 2 trial tested telitacicept (RC18) in 8 people with relapsing-remitting multiple sclerosis. The drug aims to reduce relapses by targeting B cells. The study was terminated early, so we have limited data on safety and effectiveness.
Phase 2 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug aims to stop relapses in rare brain disease
Disease control Stopped earlyThis study tested an experimental drug called RC18 in 178 people with neuromyelitis optica spectrum disorders (NMOSD), a rare disease that causes inflammation in the eyes and spinal cord. The goal was to see if RC18 could prevent relapses and slow disability. Participants had to …
Phase 3 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC